InnoCare Announces Phase III Study Results of TYK2 Inhibitor Soficitinib Meet Primary Endpoint in Patients with Atomic Dermatitis
BEIJING, July 15, 2026 (GLOBE NEWSWIRE) -- InnoCare Pharma HKEX:09969; SSE:688428, a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that registrational phase III clinical study results of novel TYK2 (Tyrosine Kinase 2) inhibitor sofici…